Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MAOA | P21397 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | OGG1 | O15527 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519424 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL1160567 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL9897387 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL15519422 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL9897385 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL1160571 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL1160569 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL9920362 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL21030435 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB | |
| SCHEMBL1160570 | 1.00 | GAA (0.45) | GAAALDH1A1MAPTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | GAA 4531/4885ALDH1A1 1632/4885MAPT 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.